Literature DB >> 6206323

Interaction between nifedipine and postsynaptic alpha 1- and alpha 2-adrenoceptors following oral pretreatment of spontaneously hypertensive rats.

J C Clapham.   

Abstract

In spontaneously hypertensive rats (SHR), oral antihypertensive doses of nifedipine exert potent inhibitory effects on pressor responses elicited by xylazine and angiotensin II, and by stimulation of the complete sympathetic outflow, suggesting that extracellular calcium is a prerequisite for responses to these stimuli. On the other hand, only those pressor responses to low doses of phenylephrine are affected by nifedipine, suggesting less dependence of phenylephrine on extracellular calcium. The results, therefore, indicate that postsynaptic alpha-adrenoceptors mediating pressor responses to neuronally released noradrenaline and phenylephrine may differ in their dependence on extracellular calcium, although they are both considered to be of the alpha 1-subtype. The evidence also suggests that this ability of nifedipine to inhibit pressor responses to neuronally released noradrenaline, as well as pressor responses to angiotensin II, contributes to the efficacy of this drug as an antihypertensive in SHR.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206323     DOI: 10.1097/00005344-198407000-00018

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Studies on the anti-vasoconstrictor activity of BRL 34915 in spontaneously hypertensive rats; a comparison with nifedipine.

Authors:  R E Buckingham
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

2.  Greater vasodepressor sensitivity to nicardipine in spontaneously hypertensive rats (SHR) compared to normotensive rats.

Authors:  J Atkinson; M Sautel; M Sonnay; J P Fluckiger; J C de Rivaz; N Boillat; M C Piton; P A Porchet; J M Armstrong; A K Fouda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-04       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.